Ovid Therapeutics (US:OVID) ZACKS·2025-08-13 14:26分组1 - Ovid Therapeutics reported a quarterly loss of $0.06 per share, better than the Zacks Consensus Estimate of a loss of $0.16, representing an earnings surprise of +62.50% [1] - The company posted revenues of $6.27 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 4,225.52%, compared to revenues of $0.17 million a year ago [2] - Ovid Therapeutics has surpassed consensus EPS estimates two times over the last four quarters and topped consensus revenue estimates three times [2] 分组2 - The stock has underperformed, losing about 41.4% since the beginning of the year, while the S&P 500 gained 9.6% [3] - The current consensus EPS estimate for the coming quarter is -$0.14 on $0.1 million in revenues, and for the current fiscal year, it is -$0.60 on $0.52 million in revenues [7] - The Zacks Industry Rank for Medical - Biomedical and Genetics is in the bottom 41% of over 250 Zacks industries, indicating potential challenges for stock performance [8]